Invesco Ltd. Biomea Fusion, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 11,191 shares of BMEA stock, worth $47,337. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,191

Previous 11,693 4.29%

Holding current value

$47,337

Previous $52,000 117.31%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.23 - $10.1 $2,123 - $5,070	-502 Reduced 4.29%	11,191 $113,000
Q2 2024 Aug 13, 2024	BUY	$4.14 - $15.3 $5,083 - $18,788	1,228 Added 11.73%	11,693 $52,000
Q1 2024 May 14, 2024	BUY	$13.92 - $19.5 $2,825 - $3,958	203 Added 1.98%	10,465 $156,000
Q4 2023 Feb 12, 2024	SELL	$8.37 - $19.8 $64,967 - $153,687	-7,762 Reduced 43.06%	10,262 $149,000
Q3 2023 Nov 13, 2023	SELL	$13.44 - $23.02 $3.12 Million - $5.34 Million	-232,129 Reduced 92.79%	18,024 $248,000
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $2.6 Million - $5.01 Million	119,819 Added 91.93%	250,153 $5.49 Million
Q1 2023 May 12, 2023	BUY	$6.8 - $32.35 $886,271 - $4.22 Million	130,334 New	130,334 $4.04 Million
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $1.82 Million - $2.6 Million	190,916 New	190,916 $1.87 Million
Q4 2021 Feb 14, 2022	SELL	$7.22 - $12.72 $1.48 Million - $2.61 Million	-205,120 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$10.0 - $15.99 $7,870 - $12,584	787 Added 0.39%	205,120 $2.46 Million
Q2 2021 Aug 17, 2021	BUY	$13.65 - $20.93 $2.79 Million - $4.28 Million	204,333 New	204,333 $3.19 Million

Others Institutions Holding BMEA

# of Institutions

104

Shares Held

17.8M

Call Options Held

1.68M

Put Options Held

410K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $124M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account